COMMUNIQUÉS West-GlobeNewswire

IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

10/01/2025 - 14:30

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million [...]

TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology

10/01/2025 - 14:30

Company Expands Reach to Government, Commercial Entities, and School Districts Amid Rising Concerns Over Spread of Respiratory Viruses such as RSV, HMPV, and H5N1 FREDERICK, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- TOMI [...]

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

10/01/2025 - 14:30

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a [...]

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

10/01/2025 - 14:30

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]

InflammX Therapeutics Announces Option Agreement with Bausch + Lomb

10/01/2025 - 14:30

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced [...]

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

10/01/2025 - 14:30

Marks a step forward in b roadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) , atypical hemolytic uremic syndrome ( aHUS ) and generalized myasthenia gravis ( gMG ) in the U . S . P [...]

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

10/01/2025 - 14:23

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with CD123-expressing AML or MDS Initial Phase 1 data read-out expected by year-end 2025 UTRECHT, The [...]

OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division

10/01/2025 - 14:05

WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

10/01/2025 - 14:05

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to [...]

NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

10/01/2025 - 14:03

BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) [...]

RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025

10/01/2025 - 14:00

MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its key [...]

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

10/01/2025 - 14:00

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE [...]

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

10/01/2025 - 14:00

By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and specialty therapies. With two new members - Innovative Medicines Group and [...]

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

10/01/2025 - 14:00

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending [...]

ORYZON to Provide Corporate Progress Updates at Several Events in January-February

10/01/2025 - 14:00

8th Sachs Annual Neuroscience Innovation Forum 14th Annual LifeSci Advisors Corporate Access Event Invest Securities BioMed Forum 2025 MidCap Events Frankfurt 2025 Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan [...]

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

10/01/2025 - 14:00

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) [...]

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

09/01/2025 - 22:30

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm , a nationally renowned sports [...]

Voting Rights and Shares Capital of the Company

09/01/2025 - 22:15

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE [...]

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

09/01/2025 - 22:15

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 09 janv. 2025 (GLOBE NEWSWIRE) -- Paris, France, le 9 janvier 2025 Place de cotation : [...]